[
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer",
        "summary": "Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors&nbsp;and Krazati (adagrasib)&nbsp;for&nbsp;KRAS G12C-mutated colorectal cancer.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-augtyro-repotrectinib-ntrk-gene-fusion-positive-solid-tumors",
        "published": "Fri, 16 Aug 2024 14:22:19 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer",
        "summary": "Listen to a soundcast of the December 9 and 12, 2022, FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer\u201d",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-tecentriq-atezolizumab-unresectable-or-metastatic-alveolar",
        "published": "Mon, 23 Jan 2023 11:54:30 EST",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approval of Vijoice (alpelisib) for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy",
        "summary": "Listen to a soundcast of the 4/5/2022 FDA approval of Vijoice (alpelisib)  for adult and pediatric patients two years of age and older with severe manifestations of PIK3CA-related overgrowth spectrum who require systemic therapy.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-vijoice-alpelisib-adult-and-pediatric-patients-two-years-age",
        "published": "Wed, 27 Apr 2022 09:38:28 EDT",
        "keywords": [
            "PIK3CA"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, & Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u22651)",
        "summary": "FDA approvals of Verzenio (abemaciclib) for adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer, &amp; Keytruda (pembrolizumab) for persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (CPS\u202f\u2265",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-verzenio-abemaciclib-adjuvant-treatment-adult-patients-hormone",
        "published": "Mon, 25 Oct 2021 12:18:46 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Lumakras (sotorasib) for patients with KRAS G12C  mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq (infigratinib) for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement",
        "summary": "Listen to a soundcast of the May 28, 2021, approvals of Lumakras for patients with KRAS G12C\u2011mutated locally advanced or metastatic non-small cell lung cancer, and Truseltiq for unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-lumakras-sotorasib-patients-kras-g12c-mutated-locally-advanced",
        "published": "Thu, 17 Jun 2021 08:57:39 EDT",
        "keywords": [
            "KRAS"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: FDA approvals of Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy & either PD-1/PD-L1 inhibitor and Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma",
        "summary": "Trodelvy (sacituzumab govitecan) for locally advanced/metastatic urothelial cancer who received platinum-containing chemotherapy &amp; either PD-1/PD-L1 inhibitor. Opdivo (nivolumab) in combination with chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma.",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-trodelvy-sacituzumab-govitecan-locally-advancedmetastatic",
        "published": "Fri, 23 Apr 2021 13:35:39 EDT",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "FDA D.I.S.C.O. Burst Edition: Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression with no eGFR, anaplastic lymphoma kinase or receptor tyrosine kinase aberrations",
        "summary": "Listen to a soundcast of the February 22nd 2021 FDA approval of Libtayo (cemiplimab-rwlc) for first-line treatment of patients with advanced NSCLC (locally advanced who are not candidates for surgical resection or definitive chemoradiation or metastatic) whose tumors have high PD-L1 expression",
        "link": "http://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-libtayo-cemiplimab-rwlc-first-line-treatment-patients-advanced-nsclc-locally",
        "published": "Fri, 12 Mar 2021 06:01:35 EST",
        "keywords": [
            "PD-L1"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.genomeweb.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.genomeweb.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.360dx.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Natera MRD Study Results Demonstrate Potential to Ressurect Failed Adjuvant Drugs",
        "summary": "<p><span><span><span>The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/natera-mrd-study-results-demonstrate-potential-ressurect-failed-adjuvant-drugs",
        "published": "Mon, 27 Jan 2025 15:47:45 EST",
        "keywords": [
            "ctDNA"
        ]
    },
    {
        "title": "Lumea to Incorporate Myriad Genetics Cancer Tests Into Digital Pathology Platform",
        "summary": "<p>Under the collaboration, the firms will make Myriad's Prolaris prostate cancer and MyRisk hereditary cancer tests available through Lumea's BxLink digital pathology platform.</p>",
        "link": "https://www.360dx.com/business-news/lumea-incorporate-myriad-genetics-cancer-tests-digital-pathology-platform",
        "published": "Wed, 05 Feb 2025 10:05:21 EST",
        "keywords": [
            "digital pathology"
        ]
    },
    {
        "title": "Angle Looks to Dual CTC, ctDNA Analysis, Illumina Tie-up to Expand Cancer Dx, CDx Business",
        "summary": "<p>Assaying both CTCs and ctDNA simultaneously offers a path to more accurate and early cancer detection and drug response monitoring.</p>",
        "link": "https://www.genomeweb.com/cancer/angle-looks-dual-ctc-ctdna-analysis-illumina-tie-expand-cancer-dx-cdx-business",
        "published": "Thu, 06 Feb 2025 14:41:30 EST",
        "keywords": [
            "CDx",
            "ctDNA"
        ]
    },
    {
        "title": "Aiosyn Growing Team, Ramping up Sales of Breast Cancer Mitosis Detection Tool",
        "summary": "<p><span><span><span>The digital pathology software developer is raising funding that would help it to increase its head count and support its Aiosyn Mitosis Breast application.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/aiosyn-growing-team-ramping-sales-breast-cancer-mitosis-detection-tool",
        "published": "Fri, 07 Feb 2025 08:45:22 EST",
        "keywords": [
            "digital pathology"
        ]
    }
]